Astria Therapeutics, Inc.

NasdaqGM:ATXS 주식 보고서

시가총액: US$627.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Astria Therapeutics 미래 성장

Future 기준 확인 0/6

Astria Therapeutics 의 수익은 연간 5.4% 감소할 것으로 예상되는 반면, 연간 수익은 92.5% 로 증가할 것으로 예상됩니다. 92.5% 연간. EPS는 연간 5.1% 만큼 성장할 것으로 예상됩니다.

주요 정보

-6.9%

수익 성장률

5.1%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률88.7%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트27 Sep 2024

최근 미래 성장 업데이트

Recent updates

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

수익 및 매출 성장 예측

NasdaqGM:ATXS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261-143-175N/A6
12/31/2025N/A-122-141N/A6
12/31/2024N/A-97-84N/A6
6/30/2024N/A-93-81-80N/A
3/31/2024N/A-82-74-74N/A
12/31/2023N/A-73-68-68N/A
9/30/2023N/A-55-49-49N/A
6/30/2023N/A-49-45-45N/A
3/31/2023N/A-48-44-44N/A
12/31/2022N/A-52-44-44N/A
9/30/2022N/A-48-39-39N/A
6/30/2022N/A-44-37-37N/A
3/31/2022N/A-65-34-34N/A
12/31/2021N/A-219-30-30N/A
9/30/2021N/A-219-32-32N/A
6/30/2021N/A-222-34-34N/A
3/31/2021N/A-199-34-34N/A
12/31/2020N/A-37-33-32N/A
9/30/2020N/A-35-32-32N/A
6/30/2020N/A-31-29-29N/A
3/31/2020N/A-28-27-27N/A
12/31/2019N/A-26-27-27N/A
9/30/2019N/A-26-24-24N/A
6/30/2019N/A-25-23-23N/A
3/31/2019N/A-24-23-23N/A
12/31/2018N/A-26-23-23N/A
9/30/20180-25-24-24N/A
6/30/20181-27-25-25N/A
3/31/20181-27N/A-26N/A
12/31/20171-27N/A-27N/A
9/30/20170-31N/A-29N/A
6/30/2017N/A-32N/A-29N/A
3/31/2017N/A-35N/A-32N/A
12/31/2016N/A-36N/A-33N/A
9/30/2016N/A-37N/A-34N/A
6/30/2016N/A-37N/A-35N/A
3/31/2016N/A-36N/A-32N/A
12/31/2015N/A-33N/A-30N/A
9/30/2015N/A-29N/A-27N/A
6/30/2015N/A-27N/A-24N/A
3/31/2015N/A-24N/A-23N/A
12/31/2014N/A-22N/A-20N/A
9/30/2014N/A-21N/A-19N/A

애널리스트 미래 성장 예측

수입 대 저축률: ATXS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ATXS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ATXS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ATXS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: ATXS 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ATXS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견